Serum Fetuin‐B Levels Are Elevated in Women with Metabolic Syndrome and Associated with Increased Oxidative Stress

Xue, Shiyao; Han, Hongdong; Rui, Shunli; Yang, Gangyi; Huang, Yizhou; Zhan, Bin; Geng, Shan; Liu, Hua; Chen, Chen; Li, Ling

doi:10.1155/2021/6657658

Cited by 10 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, whether FXR or Foxo1 is involved in activating Fetuin B in the context of obesity requires further investigation. Moreover, an increasing number of studies have focused on the association between Fetuin B in females and metabolism-related disorders, gestational diabetes mellitus and polycystic ovary syndrome 62 – 64 . It would be interesting to further investigate how Fetuin B is regulated in female mice in the future and explore any potential involvement of sex-dependent regulation mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Hepatokine Fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity

Wang

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Obesity is an expanding global public health problem and a leading cause of metabolic disorders. The hepatokine Fetuin B participates in regulating insulin resistance, glucose metabolism and liver steatosis. However, the mechanism underlying Fetuin B activation remains unclear. Our previous population-based study demonstrated a significant association between serum Fetuin B and body fat mass in an obese population, which indicates its potential in mediating obesity-related metabolic disorders. In the present study, we further revealed a significant correlation between Fetuin B and leptin, the classic adipokine released by expanding adipose tissue, in this obese population. Consistently, elevated Fetuin B and leptin levels were confirmed in diet-induced obese mice. Furthermore, an in vitro study demonstrated that the leptin signalling pathway directly activated the transcription and expression of Fetuin B in primary hepatocytes and AML12 cells in a STAT3-dependent manner. STAT3 binds to the response elements on FetuB promoter to directly activate FetuB transcription. Finally, the mediating effect of Fetuin B in insulin resistance induced by leptin was confirmed according to mediation analysis in this obese population. Therefore, our study identifies leptin-STAT3 as an upstream signalling pathway that activates Fetuin B and provides new insights into the pathogenic mechanisms of obesity-related metabolic disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatokine Fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity

Wang

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…All participants, who were outpatients, underwent physical examinations. IR was diagnosed employing a homeostasis model assessment index (HOMA-IR) > 3.0 [9], with no presence of PCOS or other metabolic diseases. The Rotterdam criteria, updated in 2003 [10], served as the diagnostic basis for PCOS patients.…”

Section: Study Populationmentioning

confidence: 99%

Dickkopf1 (DKK1) as a Potential Biomarker in Polycystic Ovary Syndrome and Insulin Resistance: A Cross-Sectional Study

Wang

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Dickkopf1 (DKK1) isa protein with established links to metabolic diseases. However, its association with polycystic ovary syndrome (PCOS) and insulin resistance (IR) remains ambiguous. Methods: We conducted a cross-sectional study involving 300 participants, including 100 healthy women, 100 women with PCOS, and 100 individuals with IR. We used the STRING database to identify proteins that interact with DKK1 and performed KEGG and GO analyses to determine the biological processes and signaling pathways that are enriched in DKK1-related proteins. Serum DKK1 levels and Adipoq were measured by ELISA kits. The expression of DKK1 in liver tissue wasdetected by western blotting. Results: Relative to the control group, both the IR and PCOS cohorts exhibited markedly elevated serum DKK1 levels and noticeably reduced Adipoq levels. Correlation analyses revealeda positive relationship between serum DKK1 levels and body mass index(BMI), waist-hip ratio (WHR), body fat percentage (FAT%), systolic blood pressure (SBP), triglycerides (TG), fasting plasma glucose (FPG), fasting insulin (FIns), glycosylated hemoglobin (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR) and a negative relationship between Adipoq levels and M-value. Multiple regression analysis indicated that BMI, FAT%, TG, and Adipoq were independent factors affecting DKK1. An analysis of multiple stepwise regressions revealed that DKK1 was a risk factor for IR and PCOS. In the euglycemic-hyperinsulinemic clamp (EHC) test, serum DKK1 levels exhibited a significant increase in the PCOS patients and a pronounced decrease in the IR patients at 30 minutes and returned to baseline at 60 minutes. Conclusions: Our research revealedthat an increase in DKK1 levels in the blood was significantly associated with PCOS and IR, thereby highlighting the potential involvement of DKK1 in the pathogenesis of PCOS and IR. This insight paves the way for further investigations into the role of DKK1 in PCOS and IR.

show abstract

“…There are two pathways to increasing insulin levels: increasing the amount of insulin produced and increasing the efficiency of glucose utilization. Instead of acting via the classical mechanism of insulin dependence to regulate blood glucose levels, fetuin-B may act via another insulin-independent mechanism, e.g., involving efficient glucose utilization [ 53 ]. The exact mechanism remains to be investigated.…”

Section: Hepatic Factorsmentioning

confidence: 99%

Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications

Chen

Liu

Kan

et al. 2022

IJMS

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is defined as a combination of a group of progressive diseases, presenting different structural features of the liver at different stages of the disease. According to epidemiological surveys, as living standards improve, the global prevalence of NAFLD increases. Acute kidney injury (AKI) is a class of clinical conditions characterized by a rapid decline in kidney function. NAFLD and AKI, as major public health diseases with high prevalence and mortality, respectively, worldwide, place a heavy burden on societal healthcare systems. Clinical observations of patients with NAFLD with AKI suggest a possible association between the two diseases. However, little is known about the pathogenic mechanisms linking NAFLD and AKI, and the combination of the diseases is poorly treated. Previous studies have revealed that liver-derived factors are transported to distal organs via circulation, such as the kidney, where they elicit specific effects. Of note, while NAFLD affects the expression of many hepatic factors, studies on the mechanisms whereby NAFLD mediates the generation of hepatic factors that lead to AKI are lacking. Considering the unique positioning of hepatic factors in coordinating systemic energy metabolism and maintaining energy homeostasis, we hypothesize that the effects of NAFLD are not only limited to the structural and functional changes in the liver but may also involve the entire body via the hepatic factors, e.g., playing an important role in the development of AKI. This raises the question of whether analogs of beneficial hepatic factors or inhibitors of detrimental hepatic factors could be used as a treatment for NAFLD-mediated and hepatic factor-driven AKI or other metabolic disorders. Accordingly, in this review, we describe the systemic effects of several types of hepatic factors, with a particular focus on the possible link between hepatic factors whose expression is altered under NAFLD and AKI. We also summarize the role of some key hepatic factors in metabolic control mechanisms and discuss their possible use as a preventive treatment for the progression of metabolic diseases.

show abstract

Serum Fetuin‐B Levels Are Elevated in Women with Metabolic Syndrome and Associated with Increased Oxidative Stress

Cited by 10 publications

References 41 publications

Hepatokine Fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity

Hepatokine Fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity

Dickkopf1 (DKK1) as a Potential Biomarker in Polycystic Ovary Syndrome and Insulin Resistance: A Cross-Sectional Study

Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications

Contact Info

Product

Resources

About